Late DLEK failure patients benefit from repeat endothelial keratoplasty

Article

Repeat endothelial keratoplasty (EK) is effective in improving corneal clarity in patients with failed deep lamellar endothelial keratoplasty (DLEK).

Repeat endothelial keratoplasty (EK) is effective in improving corneal clarity in patients with failed deep lamellar endothelial keratoplasty (DLEK), declares a study published in Cornea.

Dr Peter Kim et al., Department of Ophthalmology, Toronto Western Hospital, University of Toronto, Canada, compiled a retrospective, interventional case series on 10 eyes of 9 patients. Clinical records were reviewed of all participants who experienced failed DLEK surgery and underwent repeat EK surgery. Of the patients included in the study, 7 eyes had their failed DSEK donor disc removed and 3 eyes underwent repeat EK without the removal of the failed donor disc.

All eyes saw vast improvements in corneal clarity and visual acuity. There were no significant postoperative complications recorded after EK surgery.

It was concluded that repeat EK is a suitable and effective alternative to penetrating keratoplasty (PK). Surgery can be performed with or without removing the failed donor disc.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.